China is getting back to its pre-epidemic hustle and bustle as the country s newly adjusted COVID-19 response policy promotes both work and production resumption, driving a surge in passenger and traffic flow.
An oral antiviral agent called VV116, which is a potent anti-COVID-19 drug, is just as effective as Paxlovid in increasing the speed of clinical recovery, according to a scientific study published on Wednesday in the New England Journal of Medicine.
From offering the world s first inhaled COVID-19 vaccines and developing Omicron-targeted vaccines to rolling out second booster shots and targeted immunization plans for seniors, China s vaccination efforts have gained steam this year, according to authorities.
China will downgrade its management of COVID-19 from Class A to Class B on Jan 8, a move made possible by the reduced virulence of Omicron, expanded vaccinations and increased treatment and emergency response tools.